Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing
10:54am, Monday, 13'th Jan 2025
Eli Lilly & Co. Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill coul
Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 bln
09:10am, Monday, 13'th Jan 2025
Eli Lilly said on Monday it would acquire cancer therapy developer Scorpion Therapeutics for $2.5 billion in cash.
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
09:00am, Monday, 13'th Jan 2025
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3K α inhibitor currently in a Phase 1/2 clinical trial STX-478
Lilly sues two medical spas over copycat weight-loss drugs
05:05am, Monday, 13'th Jan 2025
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
04:46am, Saturday, 11'th Jan 2025
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Andreessen Horowitz, Eli Lilly to launch $500 million venture fund
11:32am, Friday, 10'th Jan 2025
Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.
High-cost weight loss drugs are sending employers to nutrition counseling in a boost for startups
11:08am, Friday, 10'th Jan 2025
Employers are increasingly requiring workers on GLP-1 medications to enroll in nutrition and lifestyle coaching programs. Startup Virta Health saw 60% revenue growth last year, topping $100 million, d
Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Venture Fund
08:48am, Friday, 10'th Jan 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--Andreessen Horowitz (a16z) Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partn
Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025?
08:41pm, Thursday, 09'th Jan 2025
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.
Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
11:01am, Thursday, 09'th Jan 2025
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.
LLY Falls Around 14% in 3 Months: How to Play the Stock
09:20am, Thursday, 09'th Jan 2025
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
07:27am, Thursday, 09'th Jan 2025
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli L
Eli Lilly's Zepbound obesity drug covered by Medicare for sleep apnea
07:09am, Thursday, 09'th Jan 2025
Eli Lilly and Co (NYSE:LLY)'s blockbuster obesity drug, Zepbound, can now be covered by Medicare plans for obstructive sleep apnea. A Centers for Medicare & Medicaid Services spokesperson, cited by CN
3 Stocks to Buy for 2025 That Are Practically Money Machines
04:34am, Thursday, 09'th Jan 2025
The 1976 movie All the President's Men perhaps provided one of the best three-word investing strategies around: "Follow the money." No, the film didn't use the phrase in the context of investing.
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea, CNBC reports
03:46pm, Wednesday, 08'th Jan 2025
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on Wednesday, citing the Centers for Medicare & Medicaid Services.
